[go: up one dir, main page]

PE20170306A1 - Nuevas formas de dosificacion de liberacion modificada de un inhibidor de la xantina oxidorreductasa o de inhibidores de xantina oxidasa - Google Patents

Nuevas formas de dosificacion de liberacion modificada de un inhibidor de la xantina oxidorreductasa o de inhibidores de xantina oxidasa

Info

Publication number
PE20170306A1
PE20170306A1 PE2016002815A PE2016002815A PE20170306A1 PE 20170306 A1 PE20170306 A1 PE 20170306A1 PE 2016002815 A PE2016002815 A PE 2016002815A PE 2016002815 A PE2016002815 A PE 2016002815A PE 20170306 A1 PE20170306 A1 PE 20170306A1
Authority
PE
Peru
Prior art keywords
xanthine
inhibitor
oxidor
dosage forms
release dosage
Prior art date
Application number
PE2016002815A
Other languages
English (en)
Inventor
Rajneesh Taneja
Vijay Gupte
Majid Vakilynejad
Original Assignee
Takeda Pharmaceuticals Usa Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45328897&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20170306(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceuticals Usa Inc filed Critical Takeda Pharmaceuticals Usa Inc
Publication of PE20170306A1 publication Critical patent/PE20170306A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se refiere a una forma de dosificacion modificada, que comprende un inhibidor de la xantina oxidorreductasa que despues de su administracion a un sujeto que lo necesita, presenta las siguientes caracteristicas: a) mantener una concentracion en plasma del inhibidor, mayor que 0,1 µg/ml por un periodo de entre 5 horas y 24 horas y b) producir una concentracion maxima en plasma (Cmax) del inhibidor de entre 2,5 µg/ml y 1,0 µg/ml. Un inhibidor seleccionado es acido 2-[3-ciano-4-(2-metilpropoxi)fenil]-4-metiltiazol-5-carboxilico, entre otros. Tambien se refiere a una composicion farmaceutica que lo comprende. Dicho inhibidor es util en el tratamiento de gota, hiperuricemia, entre otras
PE2016002815A 2010-06-16 2011-06-15 Nuevas formas de dosificacion de liberacion modificada de un inhibidor de la xantina oxidorreductasa o de inhibidores de xantina oxidasa PE20170306A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US35516410P 2010-06-16 2010-06-16

Publications (1)

Publication Number Publication Date
PE20170306A1 true PE20170306A1 (es) 2017-05-06

Family

ID=45328897

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2012002433A PE20130574A1 (es) 2010-06-16 2011-06-15 Nuevas formas de dosificacion de liberacion modificada de un inhibidor de la xantina oxidorreductasa o de inhibidores de xantina oxidasa
PE2016002815A PE20170306A1 (es) 2010-06-16 2011-06-15 Nuevas formas de dosificacion de liberacion modificada de un inhibidor de la xantina oxidorreductasa o de inhibidores de xantina oxidasa

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2012002433A PE20130574A1 (es) 2010-06-16 2011-06-15 Nuevas formas de dosificacion de liberacion modificada de un inhibidor de la xantina oxidorreductasa o de inhibidores de xantina oxidasa

Country Status (25)

Country Link
US (2) US9248119B2 (es)
EP (1) EP2582812B1 (es)
JP (2) JP5865904B2 (es)
KR (1) KR101872189B1 (es)
CN (1) CN103210084B (es)
AU (2) AU2011268445B9 (es)
BR (1) BR112012032033A2 (es)
CA (1) CA2801930A1 (es)
CL (1) CL2012003548A1 (es)
CO (1) CO6650415A2 (es)
EC (1) ECSP13012394A (es)
ES (1) ES2669184T3 (es)
IL (2) IL223455B (es)
JO (1) JO3450B1 (es)
MX (2) MX361138B (es)
MY (1) MY167126A (es)
NZ (1) NZ604646A (es)
PE (2) PE20130574A1 (es)
PH (1) PH12012502485A1 (es)
RU (1) RU2602188C2 (es)
SG (1) SG186301A1 (es)
TW (1) TW201202249A (es)
UA (1) UA112632C2 (es)
WO (1) WO2011159745A1 (es)
ZA (1) ZA201209386B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX339452B (es) * 2010-06-16 2016-05-27 Teijin Pharma Ltd Tableta con nucleo recubierto de liberacion controlada.
NZ605516A (en) * 2010-06-25 2015-02-27 Teijin Pharma Ltd Sustained-release therapeutic agent for hypertension and renal dysfunction
NZ605562A (en) * 2010-07-09 2013-11-29 Teijin Pharma Ltd Deuterated benzylbenzene derivatives and methods of use
WO2012153313A1 (en) * 2011-05-11 2012-11-15 Ranbaxy Laboratories Limited Pharmaceutical composition of febuxostat
WO2012172461A1 (en) * 2011-06-13 2012-12-20 Ranbaxy Laboratories Limited Pharmaceutical compositions of febuxostat
BR112014017902A2 (pt) * 2012-01-27 2017-08-22 Teijin Pharma Limited E National Univ Corporation Tottori Univ Agente terapêutico ou profilático para doenças causadas por distúrbios do metabolismo de glicose
WO2014009817A1 (en) * 2012-07-12 2014-01-16 Alembic Pharmaceuticals Limited Pharmaceutical composition of febuxostat
CN102973530B (zh) * 2012-12-14 2016-08-03 贵州信邦制药股份有限公司 一种非布索坦双层肠溶片剂及其制备方法
WO2014125504A2 (en) * 2013-02-18 2014-08-21 Hetero Research Foundation Pharmaceutical compositions of febuxostat
MX2015016494A (es) * 2013-05-31 2016-11-18 Takeda Pharmaceuticals Usa Inc Métodos de tratamiento y composiciones con inhibidores de xantina oxidasa.
EP2881116A1 (en) * 2013-12-05 2015-06-10 Ranbaxy Laboratories Limited Febuxostat composition
CN107708681A (zh) * 2015-04-20 2018-02-16 安成生物科技股份有限公司 含有双醋瑞因的制剂及使用其降低尿酸血液水平的方法
TWI684465B (zh) * 2015-04-22 2020-02-11 安成生物科技股份有限公司 含雙醋瑞因之製劑及使用其於降低尿酸血中濃度的方法
US20180344749A1 (en) * 2015-12-10 2018-12-06 Cogwellin, LLC Controlled release formulations of saliclate-releasing actives
CN106279024B (zh) * 2016-07-19 2018-09-14 华南理工大学 一种黄嘌呤氧化还原酶抑制剂及其制备方法与应用
CN106146419A (zh) * 2016-08-01 2016-11-23 沈阳药科大学 黄嘌呤氧化酶抑制剂
BR112019008388A2 (pt) * 2016-11-28 2019-07-09 Teijin Pharma Ltd fármaco terapêutico ou fármaco profilático para nefropatia diabética.
WO2018228440A1 (zh) * 2017-06-14 2018-12-20 江苏恒瑞医药股份有限公司 一种非布司他控释组合物及其制备方法
CN109721586B (zh) * 2017-10-27 2021-03-02 中国医科大学 一种5-苄基-3-吡啶基-1h-1,2,4-三唑类化合物及其制备方法和用途
CN108484494B (zh) * 2018-06-15 2021-07-30 沈阳药科大学 2-氧代-1,2-二氢吡啶-4-甲酸类化合物
CN108938591A (zh) * 2018-08-21 2018-12-07 天津双硕医药科技有限公司 一种含有非布司他的固体药物组合物
CN109157654B (zh) * 2018-11-06 2021-12-07 苏州大学 Tmx1的用途
CN111662239B (zh) * 2019-03-06 2023-07-28 中国医学科学院药物研究所 1,2,4-三唑类化合物及其制法和药物用途
US20220354855A1 (en) * 2019-10-09 2022-11-10 Mayo Foundation For Medical Education And Research Treatment for gastrointestinal disorders
CN113354616B (zh) * 2020-03-05 2024-03-26 中国医学科学院药物研究所 二芳基-1,2,4-三唑类化合物及其制法和药物用途

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100221041B1 (ko) 1990-11-30 1999-09-15 야스이 쇼사꾸 2-아릴티아졸 유도체 및 그의 약제학적 조성물
WO1996031211A1 (en) 1995-04-07 1996-10-10 Teijin Limited Protective agent for organ or tissue
US6322819B1 (en) 1998-10-21 2001-11-27 Shire Laboratories, Inc. Oral pulsed dose drug delivery system
CA2348871C (en) 1998-11-02 2009-04-14 John G. Devane Multiparticulate modified release composition
ECSP993280A (es) 1999-12-17 2001-07-27 Polimorfos de acido 2- (3- ciano -4 -isobutiloxi fenil) -4 -metil -5-tiazol carboxilico y metodo de produccion de los mismos
RU2219957C2 (ru) * 2001-11-19 2003-12-27 Пихлак Андрей Эдуардович Способ лечения подагры с помощью плазмосорбции
SI21301A (sl) * 2002-09-11 2004-04-30 LEK farmacevtska dru�ba d.d. Farmacevtska oblika z nadzorovanim sproščanjem
CN1713897B (zh) * 2002-10-16 2012-07-04 武田药品工业株式会社 控释制剂
MY148805A (en) 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
US8007827B2 (en) * 2004-04-02 2011-08-30 Impax Laboratories, Inc. Pharmaceutical dosage forms having immediate release and/or controlled release properties
FR2878159B1 (fr) 2004-11-24 2008-10-17 Flamel Technologies Sa Medicament oral a liberation modifiee d'au moins un principe actif sous forme multimicrocapsulaire
JP5159303B2 (ja) * 2005-03-03 2013-03-06 武田薬品工業株式会社 放出制御組成物
JP2008545627A (ja) 2005-05-09 2008-12-18 タツプ・フアーマシユーテイカル・プロダクツ・インコーポレイテツド 腎結石症を治療する方法
FR2891459B1 (fr) * 2005-09-30 2007-12-28 Flamel Technologies Sa Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant
ATE489079T1 (de) * 2005-12-29 2010-12-15 Osmotica Kereskedelmi Es Szolgaltata Kft Mehrschichtige tablette mit dreifacher freisetzungskombination
US20080269226A1 (en) * 2006-11-13 2008-10-30 Christopher Lademacher Methods for Preserving Renal Function Using Xanthine Oxidoreductase Inhibitors
US8110226B2 (en) * 2007-07-20 2012-02-07 Mylan Pharmaceuticals Inc. Drug formulations having inert sealed cores
JP5820269B2 (ja) 2008-05-22 2015-11-24 アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ Ｓｇｌｔ２阻害剤を使用する高尿酸血症の治療方法およびｓｇｌｔ２阻害剤を含有する組成物
CN101716132B (zh) * 2008-10-09 2012-01-11 北京方策方程医药科技有限公司 非布索坦肠溶制剂
CN101474175B (zh) 2009-01-20 2014-07-02 重庆医药工业研究院有限责任公司 一种高生物利用度非布司他口服固体制剂及其制备方法
CN101658505A (zh) * 2009-09-29 2010-03-03 北京华禧联合科技发展有限公司 非布索坦的缓释制剂及其制备方法
CN101711743B (zh) 2009-12-04 2011-08-24 山东淄博新达制药有限公司 非布索坦干混悬剂及其制备方法
CN101711751A (zh) 2009-12-04 2010-05-26 山东淄博新达制药有限公司 非布索坦分散片及其制备方法
CN101773498B (zh) 2009-12-30 2012-06-20 青岛黄海制药有限责任公司 一种含有非布司他的口服缓控释制剂的制备方法
NZ605516A (en) 2010-06-25 2015-02-27 Teijin Pharma Ltd Sustained-release therapeutic agent for hypertension and renal dysfunction
NZ605562A (en) 2010-07-09 2013-11-29 Teijin Pharma Ltd Deuterated benzylbenzene derivatives and methods of use

Also Published As

Publication number Publication date
CN103210084B (zh) 2016-04-20
AU2015204313B2 (en) 2017-11-16
MY167126A (en) 2018-08-13
BR112012032033A2 (pt) 2017-10-31
MX336607B (es) 2016-01-25
CA2801930A1 (en) 2011-12-22
PE20130574A1 (es) 2013-06-01
CN103210084A (zh) 2013-07-17
EP2582812A4 (en) 2013-12-04
TW201202249A (en) 2012-01-16
CL2012003548A1 (es) 2013-09-06
EP2582812A1 (en) 2013-04-24
JP5865904B2 (ja) 2016-02-17
AU2011268445B2 (en) 2015-05-07
KR101872189B1 (ko) 2018-06-29
NZ604646A (en) 2014-11-28
AU2015204313A1 (en) 2015-08-06
CO6650415A2 (es) 2013-04-15
ECSP13012394A (es) 2013-04-30
ES2669184T3 (es) 2018-05-24
IL264441A (en) 2019-02-28
HK1187371A1 (zh) 2014-04-04
AU2011268445B9 (en) 2015-05-07
JO3450B1 (ar) 2020-07-05
IL223455B (en) 2019-01-31
SG186301A1 (en) 2013-02-28
US20110311620A1 (en) 2011-12-22
US20160317505A1 (en) 2016-11-03
JP2013528651A (ja) 2013-07-11
ZA201209386B (en) 2016-08-31
RU2013101767A (ru) 2014-07-27
MX2012014836A (es) 2013-05-01
AU2011268445A1 (en) 2013-01-10
PH12012502485A1 (en) 2022-10-05
US9937157B2 (en) 2018-04-10
MX361138B (es) 2018-11-28
US9248119B2 (en) 2016-02-02
WO2011159745A1 (en) 2011-12-22
KR20130129826A (ko) 2013-11-29
EP2582812B1 (en) 2018-01-24
RU2602188C2 (ru) 2016-11-10
JP2016104774A (ja) 2016-06-09
UA112632C2 (uk) 2016-10-10

Similar Documents

Publication Publication Date Title
PE20170306A1 (es) Nuevas formas de dosificacion de liberacion modificada de un inhibidor de la xantina oxidorreductasa o de inhibidores de xantina oxidasa
EA201100302A1 (ru) Лечение диабета у пациентов, для которых лечение метформином является неприемлемым
CO6640311A2 (es) Compuestos, composiciones de tioacetato y métodos de uso
EA201390198A1 (ru) Гетероциклическое соединение
PE20131464A1 (es) Derivados de quinazolin-4 (3h)-ona utilizados como inhibidores de pi3 cinasa
CL2012003393A1 (es) Combinacion farmaceutica que comprende una insulina de accion prolongada y un inhibidor de la dpp-4, que es preferiblemente linagliptina; insulina basal de accion prolonagada seleccionada de insulina detemir, glargina y degludec; inhibidor de la dpp-4 preferiblemente linagliptina; y composición farmaceutica.
EA201200559A1 (ru) Способы назначения терапии пирфенидоном
CL2011002697A1 (es) Compuestos derivados de 3-[4-(oxo-dihidropiridin)bencil]-1,3-oxazin-ona hidratados, inhibidores 11beta-hsd1; composicion farmaceutica que los comprende; y su uso en el tratamiento de la diabetes
EA201290976A1 (ru) Ненуклеозидные ингибиторы обратной транскриптазы
PE20110943A1 (es) Formulacion oral solida de alisquireno
CL2012002716A1 (es) Uso de un compuesto inhibidores de dgat1 porque es útil en la prevención, demora del progreso o el tratamiento de una enfermedad o condición seleccionada a partir de quilomicronemia, síndrome de quilomicronemia familiar e hiperlipoproteinemia tipo v; un compuesto derivado de heteroarilo sustituido; composición farmacéutica.
BR112013029999A2 (pt) derivados de tiazol
EP2560642A4 (en) TREATMENT OF GICHT
EA201171399A1 (ru) Способ и композиция для улучшения всасывания лекарственных средств
MX390332B (es) Una composición farmacéutica que comprende febuxostat e inosina para usarse en el tratamiento de enfermedades en donde existe una deficiencia de atp intracelular.
WO2012161518A3 (ko) ＲＯＲα의 활성자로서의 신규한 ｔｈｉｏｕｒｅａ 유도체 및 이를 함유하는 약학적 조성물
BRPI0909211B8 (pt) formulação oral em forma de comprimido de compostos de tetraciclina
AR074214A1 (es) Inhibidores de la fosfodiesterasa tipo iii (pde iii) o agentes sensiblizantes al ca2+ para el tratamiento de la cardiomiopatia hipertrofica
PE20200846A1 (es) Compuesto de heteroarilo con contenido de nitrogeno y su uso farmaceutico
CL2020000859A1 (es) Derivados de ácido glucónico para ser usados en el tratamiento y/o prevención de infecciones microbianas.
CL2012001159A1 (es) Composicion que comprende un inhibidor de alfa-1-proteinasa (api), y como minimo, un aminoacido; kit que comprende dicha composicion que se utiliza como una composicion farmaceutica adecuada para administracion intravenosa.
UY33305A (es) Compuestos heterocíclicos inhibidores de DGAT1
UY31059A1 (es) Formulaciones de aminoacido n-halogenado
CL2012000801A1 (es) Composición farmacéutica en solución acuosa que comprende olopatadina y un compuesto derivado de quinolina sustituida, inhibidor de pde4; y uso para el tratamiento de una condición alérgica o inflamatoria del ojo, la nariz o la piel.
PE20091030A1 (es) Composiciones farmaceuticas que comprenden la combinacion de un agente antiinflamatorio no esteroideo y un agente inhibidor de la xantino oxidasa